Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.
Jimenez-Vicente C, Cardus A, Castaño-Diez S, Ramil G, Garcia-Avila S, Gomez-Perez L, Esteban D, Arribas I, Sturla AL, Lopez-Guerra M, Martinez-Roca A, Cortes-Bullich A, Perez-Valencia AI, Zugasti I, Monge I, Carcelero E, Vall-Llovera F, Vives S, Sierra J, Nomdedeu J, Oñate G, Garrido A, Pratcorona M, Pomares H, Arnan M, Guijarro F, Diaz-Beya M, Esteve J; Spanish CETLAM Group.
Jimenez-Vicente C, et al. Among authors: monge i.
Blood Cancer J. 2025 May 14;15(1):94. doi: 10.1038/s41408-025-01298-6.
Blood Cancer J. 2025.
PMID: 40368916
Free PMC article.
No abstract available.